Two to three weeks after treatment, the previously paralyzed mice began to walk. Credit: Lehrstuhl für Zellphysiologie
To date, paralysis resulting from spinal cord damage has been irreparable. With a new therapeutic approach, scientists from the Department for Cell Physiology at Ruhr-Universität Bochum (RUB) headed by Professor Dietmar Fischer have succeeded for the first time in getting paralyzed mice to walk again. The keys to this are the protein hyper-interleukin-6, which stimulates nerve cells to regenerate, and the way how it is supplied to the animals. The researchers published their report in the Journal Nature Communications from 15 January 2021.
When the communication breaks down
Spinal cord injuries caused by sports or traffic accidents often result in permanent disabilities such as paraplegia. This is caused by damage to nerve fibers, so-called axons, which carry information from the brain to the muscles and back from the skin and muscles. If these fibers are damaged due to injury or illness, this communication is interrupted. Since severed axons in the spinal cord can’t grow back, the patients suffer from paralysis and numbness for life. To date, there are still no treatment options that could restore the lost functions in affected patients.
Designer protein stimulates regeneration
In their search for potential therapeutic approaches, the Bochum team has been working with the protein hyper-interleukin-6. “This is a so-called designer cytokine, which means it doesn’t occur like this in nature and has to be produced using genetic engineering,” explains Dietmar Fischer. His research group already demonstrated in a previous study that hIL-6 can efficiently stimulate the regeneration of nerve cells in the visual system.
In their current study, the Bochum team induced nerve cells of the motor-sensory cortex to produce hyper-Interleukin-6 themselves. For this purpose, they used viruses suitable for gene therapy, which they injected into an easily accessible brain area. There, the viruses deliver the blueprint for the production of the protein to specific nerve cells, so-called motoneurons. Since these cells are also linked via axonal side branches to other nerve cells in other brain areas that are important for movement processes such as walking, the hyper-interleukin-6 was also transported directly to these otherwise difficult to access essential nerve cells and released there in a controlled manner.
Applied in one area, effective in several areas
“Thus, gene therapy treatment of only a few nerve cells stimulated the axonal regeneration of various nerve cells in the brain and several motor tracts in the spinal cord simultaneously,” points out Dietmar Fischer. “Ultimately, this enabled the previously paralyzed animals that received this treatment to start walking after two to three weeks. This came as a great surprise to us at the beginning, as it had never been shown to be possible before after full paraplegia.”
The research team is now investigating to what extent this or similar approaches can be combined with other measures to optimize the administration of hyper-Interleukin-6 further and achieve additional functional improvements. They are also exploring whether hyper-interleukin-6 still has positive effects in mice, even if the injury occurred several weeks previously. “This aspect would be particularly relevant for application in humans,” stresses Fischer. “We are now breaking new scientific ground. These further experiments will show, among other things, whether it will be possible to transfer these new approaches to humans in the future.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Consultant on Cambridge gene therapy firm acquisition pleads guilty to insider tradingon March 3, 2021 at 9:39 am
A biotech consultant who advised on Cambridge gene therapy firm Dimension Therapeutics' potential acquisition in 2017 has pleaded guilty to charges of insider trading.
- Gene Expression Analysis Market Research Report Growth Forecast 2026on March 3, 2021 at 9:34 am
Selbyville, Delaware Market Study Report Has Added A New Report On Gene Expression Analysis Market That Provides ...
- Tips to Ensure Product Comparability in Gene Therapyon March 3, 2021 at 8:00 am
Studying how manufacturing process changes affect product quality is a critical issue in the development of novel gene therapies.
- Nanoscope President to Deliver Talk on Gene Therapy for Retinal Diseases at Association for Ocular Pharmacology and Therapeutics Conferenceon March 3, 2021 at 2:30 am
Inc., a clinical-stage biotechnology company developing gene therapies for treatment of inherited retinal diseases, today announced that its President, Samarendra Mohanty, ...
- WuXiAppTec buys UK's Oxgene in all-cash takeover to get into US$2.6 billion global market for cell and gene therapyon March 3, 2021 at 1:35 am
WuXi AppTec has completed one of its largest acquisitions, buying control of a UK-based contract research and development team to help the Shanghai pharmaceutical company get into the US$2.6 billion ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Gut dysbiosis and mortality in hemodialysis patientson March 3, 2021 at 3:29 am
Little is known about the relationship between gut dysbiosis, inflammation, and adverse outcomes in patients with chronic kidney disease. We examined the association of microbial diversity with ...
- BioInvent and Transgene has enrolled first patient in Phase I/IIa trial of novel oncolytic virus BT-001 in solid tumorson February 28, 2021 at 10:58 pm
BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer ...
- Transgene and BioInvent Have Enrolled First Patient in Phase I/IIa Trial of Novel Oncolytic Virus BT-001 in Solid Tumorson February 28, 2021 at 4:30 pm
Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a ...
- Nektar Therapeutics (NKTR) Q4 2020 Earnings Call Transcripton February 25, 2021 at 10:01 pm
Q4 2020 Earnings CallFeb 25, 2021, 5:00 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorLadies and gentlemen, thank you for standing by, and ...
- Nektar Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Resultson February 25, 2021 at 8:15 am
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2020. Cash and investments in marketable securities at December 31, 2020 ...